Treatment guide for VENCLEXTA + azacitidine (AML)
A practical guide to initiating and managing treatment with VENCLEXTA + azacitidine for patients with AML.
VIALE-A trial: Key outcomes (AML)
A summary of the efficacy and safety outcomes for VENCLEXTA + azacitidine vs AZA + Placebo in previously untreated AML from the phase 3 VIALE-A trial.
Dosing Guide: 1L CLL, R/R CLL and AML
A summary of the different dosing regimens for VENCLEXTA across all registered indications, including recommended dose modifications, as well as details on risk assessment and prophylaxis for tumour lysis syndrome (TLS).
Real-World Patient Case Study 4: Michael (AML)
A real-life case study submitted by Dr Jason Butler, documenting his experience of initiating and monitoring treatment with VENCLEXTA® for a newly diagnosed AML patient.
PBS Criteria Leaflet for VENCLEXTA in AML
A leaflet outlining the clinical criteria and codes relevant to accessing VENCLEXTA + azacitidine on the PBS for appropriate patients with AML.
VENCLEXTA Product Information (PI)
Download the PI to gain more information about VENCLEXTA.
PATIENT RESOURCES
Patient information brochure for VENCLEXTA + azacitidine treatment (AML)
Share this resource with your AML patients to help support them during VENCLEXTA + azacitidine treatment.
VENCLEXTA Consumer Medicines Information (CMI)
Download the CMI to provide your patients more information about VENCLEXTA.
Contact
Discover more about how we can help you in your practice.
PBS Information
Venclexta: VENCLEXTA (venetoclax) in combination with rituximab is PBS listed for relapsed or refractory chronic lymphocytic leukaemia (CLL). VENCLEXTA in combination with obinutuzumab is PBS listed for first line treatment of CLL or small lymphocytic lymphoma (SLL). VENCLEXTA in combination with azacitidine is PBS listed for treatment of acute myeloid leukaemia (AML). General Schedule listing. Authority required (telephone). Refer to PBS schedule for full authority information. VENCLEXTA monotherapy is not listed on the PBS. VENCLEXTA in combination with low-dose cytarabine is not listed on the PBS for treatment of AML.
Please review the full Product Information (PI) before prescribing, available below.
1L: first-line. AML: acute myeloid leukaemia. AZA: azacitidine. CI: confidence interval. CLL: chronic lymphoytic leukaemia. HR: hazard ratio. ITT: intention-to-treat. R/R CLL: relapsed or refractory CLL. TLS: tumour lysis syndrome. VEN: VENCLEXTA.
AU-VENA-210065. Last revised February 2023